Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.53 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400916 | 1.00 | CRBN (0.55) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL24821312 | 0.89 | CRBN (0.56) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL30805366 | 0.88 | CRBN (0.55) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL25438587 | 0.87 | CRBN (0.60) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL22906959 | 0.87 | CRBN (0.56) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL25473074 | 0.86 | CRBN (0.57) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL25473073 | 0.86 | CRBN (0.59) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL17859116 | 0.86 | CRBN (0.71) | CRBNDDB1 | |
| SCHEMBL20791980 | 0.86 | CRBN (0.71) | CRBNDDB1 | |
| SCHEMBL18476414 | 0.86 | CRBN (0.71) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4426286-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | Relay Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | CRBN 19/4885DDB1 1295/4885CSNK1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.